Home › Funds › Fairmount Funds Management LLC › IKT

Fairmount Funds Management LLC position in IKT

INHIBIKASE THERAPEUTICS INC · Health Care

Fairmount Funds Management LLC reported holding 8,625,000 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$17.5M, representing 1.16% of its reported portfolio and ranking #12 among its reported holdings. Fairmount Funds Management LLC has disclosed IKT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)8.62M sh
Reported value held$17.51M
Portfolio Weight1.16%
First reportedQ4 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Fairmount Funds Management LLC's IKT position evolved

Fairmount Funds Management LLC first disclosed a stake in IKT in Q4 2024 at 6,125,000 shares (US$19.9M). Across 7 filings, Fairmount Funds Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 8,625,000 shares valued at US$17.5M. Notable position changes include a 41% increase in Q4 2025 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 6.12M $19.91M New
Q1 2025 6.12M $13.41M Hold
Q2 2025 6.12M $11.94M Hold
Q3 2025 6.12M $9.92M Hold
Q4 2025 8.62M $17.68M Add
Q1 2026 8.62M $14.49M Hold
Q2 2026 8.62M $17.51M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IKT and 13F data

IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.4M), Soleus Capital Management, L.P. (US$22.1M), Trails Edge Capital Partners, LP (US$18.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IKT

All IKT fund holders →

FAQ

How long has Fairmount Funds Management LLC held IKT?

Fairmount Funds Management LLC has disclosed IKT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Fairmount Funds Management LLC's current position in IKT?

As of Q2 2026, Fairmount Funds Management LLC holds 8.62M shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $17.51M, representing 1.16% of its reported portfolio and ranking #12.

Has Fairmount Funds Management LLC been buying or selling IKT?

In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in IKT.

Which other funds hold IKT?

Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, among 69 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.